US2008161241A1PendingUtilityA1

Inhibitor of cardiac tachyarrhythmias

47
Individually held — no corporate assignee on recordPriority: Aug 28, 2003Filed: Sep 11, 2007Published: Jul 3, 2008
Est. expiryAug 28, 2023(expired)· nominal 20-yr term from priority
Inventors:David C. KemEugene Patterson
A61P 9/10A01K 2267/0375A61K 38/1793A61K 38/06A61K 38/20
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of preventing sustained monomorphic ventricular tachycardia following myocardial ischemia, decreasing infarct size and/or decreasing the incidence and/or maximum intrinsic rate of very rapid ventricular triplets following myocardial ischemia is disclosed. The methods involve administering an effective amount of a composition that inhibits substantial loss of beta-adrenergic receptor kinase (β-ARK) activity and/or β-ARK expression.

Claims

exact text as granted — not AI-modified
1 . A method of preventing sustained monomorphic ventricular tachycardia in a patient following myocardial ischemia, wherein the patient is experiencing acute myocardial infarction, the method comprising the step of:
 administering to the patient an effective amount of a composition comprising etanercept, wherein the composition inhibits substantial loss of at least one of beta-adrenergic receptor kinase activity and beta-adrenergic receptor kinase expression, and wherein the administration of the composition reduces the occurrence of sustained monomorphic ventricular tachycardia.   
     
     
         2 . The method of  claim 1 , wherein the administration of the composition results in the prevention of the degradation of beta-adrenergic receptor kinase in response to myocardial ischemia. 
     
     
         3 . The method of  claim 1 , wherein the administration of the composition results in a retention of at least about 10% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         4 . The method of  claim 1 , wherein the administration of the composition results in a retention of at least about 20% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         5 . The method of  claim 1 , wherein the administration of the composition results in a retention of at least about 30% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         6 . The method of  claim 1 , wherein the administration of the composition results in a retention of at least about 40% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         7 . The method of  claim 1 , wherein the administration of the composition results in a retention of at least about 50% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         8 . A method of preventing sudden cardiac death in a patient following myocardial ischemia, wherein the patient is experiencing acute myocardial infarction, the method comprising the step of:
 administering to the patient an effective amount of a composition comprising etanercept, wherein the composition inhibits substantial loss of at least one of beta-adrenergic receptor kinase activity and beta-adrenergic receptor kinase expression, and wherein the administration of the composition reduces the occurrence of sudden cardiac death.   
     
     
         9 . The method of  claim 8 , wherein the administration of the composition results in the prevention of the degradation of beta-adrenergic receptor kinase in response to myocardial ischemia. 
     
     
         10 . The method of  claim 8 , wherein the administration of the composition results in a retention of at least about 10% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         11 . The method of  claim 8 , wherein the administration of the composition results in a retention of at least about 20% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         12 . The method of  claim 8 , wherein the administration of the composition results in a retention of at least about 30% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         13 . The method of  claim 8 , wherein the administration of the composition results in a retention of at least about 40% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         14 . The method of  claim 8 , wherein the administration of the composition results in a retention of at least about 50% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         15 . A method of decreasing infarct size following myocardial ischemia, comprising the step of:
 administering to a patient an effective amount of a composition that inhibits substantial loss of at least one of beta-adrenergic receptor kinase activity and beta-adrenergic receptor kinase expression, wherein the composition comprises etanercept.   
     
     
         16 . A method of preventing sustained monomorphic ventricular tachycardia in a patient following myocardial ischemia, wherein the patient is experiencing acute myocardial infarction, the method comprising the step of:
 administering to the patient an effective amount of a composition comprising bortezomib, wherein the composition inhibits substantial loss of at least one of beta-adrenergic receptor kinase activity and beta-adrenergic receptor kinase expression, and wherein the administration of the composition reduces the occurrence of sustained monomorphic ventricular tachycardia.   
     
     
         17 . The method of  claim 16 , wherein the administration of the composition results in the prevention of the degradation of beta-adrenergic receptor kinase in response to myocardial ischemia. 
     
     
         18 . The method of  claim 16 , wherein the administration of the composition results in a retention of at least about 10% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         19 . The method of  claim 16 , wherein the administration of the composition results in a retention of at least about 20% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         20 . The method of  claim 16 , wherein the administration of the composition results in a retention of at least about 30% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         21 . The method of  claim 16 , wherein the administration of the composition results in a retention of at least about 40% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         22 . The method of  claim 16 , wherein the administration of the composition results in a retention of at least about 50% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         23 . A method of preventing sudden cardiac death in a patient following myocardial ischemia, wherein the patient is experiencing acute myocardial infarction, the method comprising the step of:
 administering to the patient an effective amount of a composition comprising bortezomib, wherein the composition inhibits substantial loss of at least one of beta-adrenergic receptor kinase activity and beta-adrenergic receptor kinase expression, and wherein the administration of the composition reduces the occurrence of sudden cardiac death.   
     
     
         24 . The method of  claim 23 , wherein the administration of the composition results in the prevention of the degradation of beta-adrenergic receptor kinase in response to myocardial ischemia. 
     
     
         25 . The method of  claim 23 , wherein the administration of the composition results in a retention of at least about 10% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         26 . The method of  claim 23 , wherein the administration of the composition results in a retention of at least about 20% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         27 . The method of  claim 23 , wherein the administration of the composition results in a retention of at least about 30% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         27 . The method of  claim 23 , wherein the administration of the composition results in a retention of at least about 40% of beta-adrenergic receptor kinase activity under non-ischemic conditions. 
     
     
         28 . The method of  claim 23 , wherein the administration of the composition results in a retention of at least about 50% of beta-adrenergic receptor kinase activity under non-ischemic conditions.

Join the waitlist — get patent alerts

Track US2008161241A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.